Prospectus Finalizes Resale of 5.5 Million Shares by Sermonix Pharmaceuticals

summarizeSummary

LeonaBio filed a prospectus supplement enabling Sermonix Pharmaceuticals to resell 5.5 million shares, representing a substantial potential dilution for existing shareholders.

check_boxKey Events

• Resale of 5.5 Million Shares Enabled

  This prospectus supplement allows Sermonix Pharmaceuticals, Inc. to sell up to 5,502,402 shares of common stock, which were issued upon the exercise of a pre-funded warrant.

• Significant Potential Dilution

  The shares represent approximately 58% of LeonaBio's currently outstanding common stock, creating a substantial overhang on the market.

• Minimal Proceeds to Company

  LeonaBio will receive only approximately $5,502 from the cash exercise of the pre-funded warrant, not from the subsequent sale of shares by Sermonix.

• Follows Prior Registration

  This filing operationalizes the resale program previously registered via an S-1/A on March 31, 2026.

auto_awesomeAnalysis

This 424B3 prospectus supplement finalizes the ability for Sermonix Pharmaceuticals, Inc. to resell up to 5,502,402 shares of LeonaBio common stock. These shares were issued upon the exercise of a pre-funded warrant received as partial consideration for a December 2025 License Agreement. While LeonaBio will only receive approximately $5,502 from the warrant exercise, the potential sale of these shares by Sermonix represents a significant overhang, as it could introduce a large block of stock (approximately 58% of current outstanding shares) into the market. This follows the S-1/A registration filed on March 31, 2026, which initially registered these shares for resale.